Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist
28/04/2026 02:29
April 28 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX: CLINUVEL UPDATE ON LEVEL II ADR UPGRADE, NASDAQ UPLIST CONTINUES SEC ENGAGEMENT FOR NASDAQ ADR UPLISTING PLANS LEVEL II ADR UPGRADE AND NASDAQ LISTING AS CUVL EXPECTS SEC REVIEW TO COMPLETE BEFORE END OF FY2026 Further company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist